Premier Alternatives

Reprieve Cardiovascular

Milford, MA · Founded 2018 · Privately Held (backing)

Developer of an acute decompensated heart failure (ADHF) treatment medical device designed to help patients experience life without limits. Reprieve Cardiovascular is based in Milford, MA and was founded in 2018. It was valued at $100 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $103 million across 5 recorded rounds; the latest was a $30.9 million early-stage round in May 2025.

PMV mark · valuation
$100.0M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$103.0M
Last round
Early Stage VC
May 2025

Reprieve Cardiovascular key facts

as of Oct 2026
  • Developer of an acute decompensated heart failure (ADHF) treatment medical device designed to help patients experience life without limits.
  • Reprieve Cardiovascular is valued at approximately $100.0M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $103.0M across 5 recorded rounds; the latest was Early Stage VC ($30.9M) in May 2025.
  • Notable investors include Deerfield Management, Arboretum Ventures, Lightstone Ventures, Abiomed, Cadence Capital — 11 tracked in total.
  • Reprieve Cardiovascular has filed 6 Form Ds with the SEC since 2020, most recently Jun 2025 ($30.9M sold to 12 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$100.0M

Valued at $100.0M at its later-stage round, Sep 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Reprieve Cardiovascular with a free account
  • ·The complete investor list: 11 names
  • ·Watch Reprieve Cardiovascular: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Reprieve Cardiovascular funding rounds

5 rounds
May 2025Early Stage VC$30.9MSEC filing▮
Sep 2024Debt$9.5MSEC filing▮
Nov 2023Early Stage VC$12.1MSEC filing▮
Apr 2022Early Stage VC$15.0MSEC filing▮
Jul 2020Early Stage VC$15.0MSEC filing▮
Full funding history →

Reprieve Cardiovascular valuation

Reprieve Cardiovascular was valued at $100 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Reprieve Cardiovascular raised?

Reprieve Cardiovascular has raised $103 million across 5 recorded rounds since 2020. The largest was a $9.5 million debt round in Sep 2024; the most recent was a $30.9 million early-stage round in May 2025.

Reprieve Cardiovascular has filed 6 Form Ds with the SEC since 2020, most recently in Jun 2025 ($30.9 million sold to 12 investors).

Reprieve Cardiovascular investors

11 investors are on record for Reprieve Cardiovascular, including Deerfield Management, Arboretum Ventures, Lightstone Ventures and Abiomed. The early-stage round in May 2025 drew 12 investors.

About Reprieve Cardiovascular

Developer of an acute decompensated heart failure (ADHF) treatment medical device designed to help patients experience life without limits. The company's device offers a proprietary method of diuretic therapy that provides precise and predictable management of a patient's fluid levels, guarding against dangerous fluid imbalances and controls over diuretic therapy, enabling medical practitioners to ensure a quality of life for the patient.

Sector
Healthcare
HQ
Milford, MA, United States
Founded
2018
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.